Trial
NCT00564876
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Duke University
Collaborators
Bristol-Myers Squibb
Condition
Carcinoma, Non-Small-Cell Lung
Intervention
Dasatinib
Why stopped
Lack of accrual, study closed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-02-23